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5-Aminolevulinic acid synthase (ALAS-1) is the first rate con-
trolling enzyme that controls cellular heme biosynthesis. Nega-
tive feedback regulation of ALAS-1 by the end product heme is
well documented and provides the foundation for heme treat-
ment of acute porphyrias, a group of diseases caused by genetic
defects in the heme biosynthesis pathway and exacerbated by
controlled up-regulation of ALAS-1. Heme is known to affect
ALAS-1 activity by repressing gene transcription, accelerating
mRNA degradation, and impeding pre-ALAS-1 mitochondrial
translocation. In the current study, we examined the effect of
heme on the rate of mature ALAS-1 protein turnover in human
cells and tissues and explored the mediator involved in this new
regulatory mechanism.We found that heme and other metallo-
porphyrins such as CoPP and CrPP decreased mitochondrial
ALAS-1 protein through proteolysis. This degradative effect
cannot be emulated by iron or free protoporphyrin, two major
chemical components of the heme ring, and is independent of
oxidative stress. Down-regulating the activity of mitochondrial
LONP1, an ATP-dependent protease that controls the selective
turnover of mitochondrial matrix proteins, with potent inhibi-
tors and specific siRNA diminished the negative effect of heme
on mitochondrial ALAS-1. Therefore, our data support the
existence of a conserved heme feedback regulatory mechanism
that functions on the mature form of ALAS-1 protein through
the activity of a mitochondrial proteolytic system.
The iron-protoporphyrin (heme) macrocycle is a primordial
molecule that carries out a myriad of essential functions upon
which most aerobic life on earth depends. The essential func-
tions of heme in the transport of oxygen and carbon dioxide in
the blood (hemoglobin) and in diverse other tissues (myoglo-
bin, neuroglobin) are well known, as is its essential role in cat-
alyzing and accelerating numerous redox reactions, as an essen-
tial prosthetic group for cytochromes, peroxidases, and
oxygenases. In most animals, heme is synthesized from glycine
and succinyl-CoA in a complex pathway involving eight
enzymes. The first and normally rate-controlling step is carried
out by the mitochondrial enzyme 5-aminolevulinic acid syn-
thase (ALAS).3 The ubiquitous, housekeeping isoform of ALAS
is ALAS-1 (ALAS-1), levels of which can be increased remark-
ably by numerous drugs and chemicals through interactions
with several nuclear receptors (e.g.CAR, PXR, and RXR), which
form heterodimers and act as positive transcription factors for
the ALAS-1 gene, as well as those of cytochromes P-450, the
hemoproteins chiefly responsible for phase I metabolism of
numerous endogenous intermediates and xenobiotics (1–5). In
contrast, heme, the end product of the synthetic pathway,
exerts potent down-regulation of expression ofALAS-1 inmost
tissues, an example of negative feedback repression (1, 6). Glu-
cose and other metabolizable sugars also down-regulate the
expression of ALAS-1, acting chiefly through a transcriptional
co-activator, PGC-1 (7).
Uncontrolled up-regulation of ALAS-1 is a biochemical hall-
mark and sine qua non of acute attacks of hepatic porphyrias, a
group of largely inherited disorders inwhich variable degrees of
deficiency in an enzyme of normal hepatic heme synthesis dis-
tal to ALAS-1 (e.g. ALA dehydratase, porphobilinogen deami-
nase, coproporphyrinogen oxidase, or protoporphyrinogen
oxidase). Such deficiency, especially when coupled with
another factor that increases the need of the liver for heme (e.g.
for induction of cytochromes P-450) and/or the rate of hepatic
heme breakdown (e.g. suicide substrates of cytochromes
P-450), leads to derepression of ALAS-1 and thus to marked
increases in ALA, porphobilinogen, and other intermediates
proximal to the site of the metabolic block in the heme syn-
thetic pathway (1, 8, 9).
In view of the above, it is not surprising that glucose loading
and intravenous infusions of heme, which both repress
ALAS-1, and, in the case of heme, also restores the normal
hepatic heme pools; hence, over the years, these treatments
remain the mainstays of therapy of acute porphyric attacks (1,
10, 11).
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We and others (12, 13) have shown that heme down-regu-
lates expression of the hepatic ALAS-1 gene in several ways,
including diminution of gene transcription and enhancement
of the breakdown of the mRNA (14–16). In addition, heme has
been shown to block the uptake of pre-ALAS-1 into mitochon-
dria (17, 18), where the translocation signal sequence on the
pre-ALAS-1 protein is cleaved and processed into the mature
form. This step is essential for activity of the synthase because
succinyl-CoA is synthesized in and present in meaningful con-
centrations only within the mitochondria.
In a previous effort to further extend our understanding of
ALAS-1 regulation by heme and non-hememetalloporphyrins,
we examined the changes in the ALAS-1 protein level in
response to exogenous metalloporphyrin treatment. Our data
showed varied protein expression patterns. Heme and cobalt
protoporphyrin (CoPP) significantly decreased the amount of a
protein with a molecular weight corresponding to the mature
form of ALAS-1, while increasing the level of a higher molecu-
lar weight form that matched the size of the precursor protein
(19). These results led us to speculate a new level of regulation
by heme that functions on affecting the protein turnover rate.
Recently, studies performed in rats provided evidence that
heme is also capable of enhancing the rate of disappearance
(presumably breakdown) of ALAS-1 in mitochondria (20).
Because of the importance of the synthase in human health
and disease (the acute porphyrias), and in view of the mani-
fold and still unfolding roles of heme in human biology and
pathophysiology, we have assessed the effects of heme and
other selected metalloporphyrins on the stability of ALAS-1
in mitochondria from human liver cells. We also have
explored the mechanisms whereby heme leads to decreased
levels of ALAS-1 in mitochondria.
EXPERIMENTAL PROCEDURES
Chemicals and Reagents—Protoporphyrin IX (PP), iron pro-
toporphyrin (heme), CoPP, chromium protoporphyrin (CrPP),
and manganese protoporphyrin (MnPP) were purchased from
Frontier Scientific (Logan, UT). Dimethyl sulfoxide (DMSO)
was purchased from Fisher Biotech (Fair Lawn, NJ). Rabbit
anti-ALAS-1 polyclonal antibody and mouse anti-VDAC1/
porin monoclonal antibody were from Abcam (Cambridge,
MA); iron(III) chloride (FeCl3), 4,6-dioxoheptanoic acid, buty-
lated hydroxytoluene (BHT), tert-butyl hydroperoxide solu-
tion, sucrose, Tween 20, MOPS, CA-074 methyl ester, epox-
omicin, rabbit anti-LONP1 polyclonal antibody, and protease
inhibitormixture (P8340) were from Sigma-Aldrich; and rabbit
anti-calnexin polyclonal antibody, goat anti-human GAPDH
polyclonal antibody, mouse anti-rabbit IgG (ALAS-1, LONP1,
and calnexin), goat anti-mouse IgG (VDAC1/Porin), and don-
key anti-goat IgG (GAPDH) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). BCA protein assay reagent
was from Pierce. ECL-Plus was purchased from Amersham
Biosciences. MG-262 and InnoZyme Cathepsin B Activity
Assay Kit were fromEMDChemicals (Gibbstown, NJ). The 20S
Proteasome Assay Kit was from Cayman Chemical Company
(AnnArbor,MI). DMEM, PBS, pH 7.4 (1), penicillin-strepto-
mycin, FBS, and trypsin were from Invitrogen. 7.5% gradient
SDS-PAGE gels, nonfat dry milk, and ImmunBlot PVDFmem-
branes were purchased from Bio-Rad.
Cell Line and Culture Conditions—Huh-7, the human hepa-
tocellular carcinoma cell line, was purchased from the Japan
Health Research Resources Bank (Osaka, Japan). HepG2,
another human liver hepatocellular carcinoma cell line, was
obtained from the American Type Culture Collection (Manas-
sas, VA). The Huh-7.5 cell line was from Apath LLC (St, Louis,
MO). Huh-7.5 is a highly permissive, interferon-curedHuh-7
human hepatocellular carcinoma cell line derivative. All cells
were maintained in DMEM supplemented with 100 units/ml
penicillin, 100 g/ml streptomycin, and 10% (v/v) FBS. All cells
were maintained in a humidified atmosphere of 95% room air
and 5% CO2 at 37 °C.
Human Liver Tissue—Liver biopsies were obtained from
subjects without known liver disease who were undergoing
laparoscopic upper abdominal surgery for other therapeutic
indications (e.g. cholecystectomy and gastric-bypass surgery).
Wedge biopsies (1 g) were obtained and placed immediately
into buffer (250 mM sucrose, 5 mM MOPS, pH 7.2), put on ice,
and transported to the laboratory. The protocol for obtaining
human liver samples was received and approved by the Institu-
tional Review Board of Carolinas Medical Center.
siRNA Transfection—A SMARTpool of siRNAs was
purchased from Dharmacon (Lafayette, CO). Transfections of
human LONP1 siRNAs and the nonspecific scrambles (control
siRNAs) were performed with LipofectamineTM 2000 from
Invitrogen as described previously (21). Huh-7 cells were plated
in 24-well plates 1 day prior to transfection and transfected at
7080% confluence. Cells were exposed to transfection
medium for 48 h with siRNAs before harvesting.
Cathepsin B Activity—Cathepsin B activity was measured
using an InnoZyme Cathepsin B Activity Assay Kit (EMD
Chemicals). The manufacturer’s protocol was followed.
20 S Proteasomal Activity—The 20 S proteasome activity was
determined in cell or mitochondrial extracts using the 20 S
Proteasome Assay Kit (Cayman Chemical) as described by the
manufacturer. The assay is based on the detection of the
fluorophore 7-amino-4-methylcoumarin (AMC). SUC-LLVY-
AMC was used as substrate in this assay. The fluorescence of
AMC is quenched by LLVY, upon cleavage into two separate
fragments by the 20 S proteasome, the fluorescence of AMC is
recovered and can be quantified. Therefore, relative fluores-
cence units of AMC is ameasurement of 20 S proteasome activ-
ity (excitation, 360 nm; emission, 480 nm).
Isolation of Mitochondria and Electron Microscopy—Har-
vested cells or fresh human liver tissue were homogenized
gently in the buffer that contained 250 mM sucrose and 20 mM
MOPS (pH 7.2) on ice and then were spun down by conven-
tional differential centrifugation with a final spin at 8600  g.
The mitochondria were suspended in 250 mM sucrose and 5
mM MOPS (pH 7.2). Mitochondrial protein was determined
using the PierceCoomassie protein assay reagent kit. Themito-
chondria-enriched pellets, prepared by differential centrifuga-
tion, were fixed in 4% glutaraldehyde, stained with osmium
tetroxide, sectioned at 1 micron, and examined by electron
microscopy. Representative fields were photographed.
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Western Immunoblotting Analysis—Protein preparations
and Western immunoblotting were carried out as described
previously (19). In brief, total proteins (75 g) were separated
on 7.5% gradient SDS-PAGE gels. After electrophoretic trans-
fer onto Immun-Blot PVDF membranes, the membranes were
blocked for 1 h in PBS containing 5% nonfat dry milk and 0.1%
Tween 20 and then incubated overnight with primary antibody
at 4 °C. The dilutions of the primary antibodies were as follows:
1:5000 for anti-ALAS-1, 1:2000 for VDAC1/porin, 1:1000 for
anti-LONP1, 1:1000 for anti-calnexin, and 1:1000 for anti-
GAPDH. Membranes were then incubated for 1 h with horse-
radish peroxidase-conjugated secondary antibodies (1:10,000
dilution). Finally, the bound antibodies were visualizedwith the
ECL-Plus chemiluminescence system according to the manu-
facturer’s protocol (Amersham Biosciences). A Kodak 1DV3.6
computer-based imaging system (Eastman-Kodak, Rochester,
NY) was used to measure the relative optical density of each
specific band obtained afterWestern immunoblotting analysis.
Data are expressed as percentage of the vehicle control
(DMSO).
Statistical Analysis—Experiments were repeated aminimum
of three times with similar results. All experiments included at
least triplicate samples for each treatment group. Representa-
tive results from a single experiment are presented. Initial
inspection showed that the results were normally distributed.
Therefore, parametric statistical procedures were used. Statis-
tical analyses of data were performed with JMP 6.0.3 software
(SAS Institute, Cary, NC). Student’s t test for comparisons of
two means and analysis of variance (F statistics) for compari-
sons of more than two, with pair-wise comparisons by the
Kruskal-Wallis test were performed when appropriate. Values
of p  0.05 were considered significant.
RESULTS
Mitochondrially Enriched Subcellular Fractions—Transmis-
sion electron micrographs of the subcellular fractions enriched
for mitochondria revealed abundant, intact mitochondria with
numerous cristae, as well as circular membrane-bound struc-
tures of various sizes (Fig. 1A). These fractions contained
VDAC1/porin protein and the lower molecular mass (68 kDa)
formofALAS-1 but not the highermolecularmass pre-ALAS-1
(Fig. 1B). They contained no detectable GAPDH (a marker of
soluble cytosolic protein) or calnexin (a marker of endoplasmic
reticulum/microsomes).
Effect of Heme on Human Mitochondrial ALAS-1—Com-
pared with vehicle (DMSO) alone, addition of heme (0.1–10
M) to mitochondrially enriched fractions led to a tempera-
ture- and time-dependent decrease in detectable ALAS-1 (data
not shown). The effects weremaximal at 1M exogenous heme
added and increased progressively with length of incubation
(0–8 h) (Fig. 2A). The effects observed at 30 °C, the tempera-
ture routinely used, were abolishedwhen incubationswere per-
formed at 0 °C (results not shown). Effects of hemewere similar
whenmitochondrially enriched fractions ofHuh-7, Huh-7.5, or
HepG2 homogenates were compared (Fig. 2B). The half-life of
ALAS-1 protein was 8.7 h in the absence of heme (DMSO as
vehicle) but only 3.4 h (2.5-fold decrease) in the presence of
heme 1 M (Fig. 2C). Depletion of endogenous heme using a
heme synthetic inhibitor, 4,6-dioxoheptanoic acid, a potent
inhibitor of heme synthesis, increased ALAS-1 protein stability
(to 57.1 h). Additionally, heme also markedly decreased
ALAS-1 protein levels in mitochondria isolated from human
liver biopsies (Fig. 2D).
Effect of Iron, Free Protoporphyrin, Oxidative Stress, andNon-
heme Metalloporphyrins on ALAS-1 Expression—Heme is a
porphyrin ring coordinated with an iron molecule. To further
dissect the mechanism(s) of action of heme on mitochondrial
ALAS-1, we also tested the effect of iron and free protoporphy-
rin on the fate of ALAS-1; neither affected expression, suggest-
ing the requirement of an intact heme macrocycle for ALAS-1
regulation (Fig. 3A).
Mitochondria harbor cellular respiration machinery that is a
major source of intracellular reactive oxygen species. Free cel-
lular heme as the main carrier of redox-active iron can syner-
gize with mitochondria-derived reactive oxygen species and
further promote oxidative stress. To evaluate whether the pro-
oxidant property of heme contributes to the observed ALAS-1
down-regulation, we treated mitochondrial preparations with
tert-butyl hydroperoxide solution, an oxidant, and BHT, an
antioxidant, in the presence or absence of heme. Tert-butyl
hydroperoxide solution treatment resulted in decreased
ALAS-1 expression (Fig. 3B), whereas BHT alone slightly
increased ALAS-1 half-life (Fig. 3C), implying that redox regu-
lation ofALAS-1may exist. However, BHTdid not affect heme-
induced ALAS-1 down-regulation (Fig. 3D), strongly suggest-
ing that heme exerts its effect onALAS-1 through amechanism
independent of oxidative stress. Addition of other metallopor-
phyrins (1 M), especially cobalt or chromium protoporphyrin,
also led to a decrease in ALAS-1 protein in mitochondrially
enriched fractions from Huh-7 cells or human liver tissue
(Fig. 3E).
FIGURE 1. Mitochondrial preparations from human hepatocytes and cell
lines. HepG2 cells were cultured, harvested, homogenized, and mitochondri-
ally enriched fractions prepared as described under “Experimental Proce-
dures.” Mitochondria-enriched pellets (75 g of protein) were visualized by
transmission electron microscopy (panel 1  13,500; panels 2 and 3 
92,000 (A)), and total cell and mitochondrial extracts from human liver biop-
sies were subjected to Western immunoblotting analysis for ALAS-1 protein
expression (B). VDAC1/porin, calnexin, and GAPDH expression served as mito-
chondrial, endoplasmic reticulum/microsome, and total lysate controls,
respectively.
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Effect of Protease Inhibitors on ALAS-1—Aprotease inhibitor
mixture consisting of aprotinin, leupeptin, bestatin, pepstatin
A, and E-64, inhibiting awide spectrumof protease activity that
might be present in the mitochondrial preparations, was used
to determine whether protein degradation accounts for
reducedALAS-1 protein expression inmitochondria. Themix-
ture increased the amount of mitochondrial ALAS-1 in the
absence of heme and alsominimized the down-regulating effect
of heme on ALAS-1 (Fig. 4A), suggesting that a proteolytic
event is involved in mitochondrial regulation of ALAS-1.
CA-074 Me, a selective inhibitor of cathepsin B, produced a
profound and durable inhibition of activity of this lysosomal
enzyme (supplemental Fig. S1). Nevertheless, even in the pres-
ence of such inhibition, heme continued to exert its down-reg-
ulatory effect on ALAS-1 protein (Fig. 4B).
MG-262 is a potent boron-containing inhibitor of Lon pro-
tease. Addition of MG-262 (10 M), either 4 h prior to, or con-
current with, the addition of heme (1 M), led to a complete
abrogation of the heme effect to accelerate the disappearance of
ALAS-1 protein (Fig. 4C). In fact, under both heme and no
heme conditions, MG-262 slightly increased the level of
ALAS-1 protein compared with null MG-262 treatment, sug-
gesting that the inhibitory function of MG-262 stabilized
ALAS-1. The greater selectivity of MG-262 for and the higher
potency against 20S proteasome over LONP1 raises concern
about the proteasomal involvement in this process. Indeed, we
FIGURE 2. Effects of heme on ALAS-1 protein expression in mitochondria from human hepatocytes and cell lines. A, mitochondrial fractions (75 g of
protein) were incubated at 30 °C with heme (1 M) for indicated time period to examine the time course of the heme effect. MW, molecular weight.
B, mitochondria from various liver cell lines were incubated with buffer, DMSO, or heme for 8 h, and ALAS-1 protein levels were assessed by Western
immunoblotting analysis. C, ALAS-1 protein half-life was determined by quantifying band intensities of remaining ALAS-1 protein normalized to VDAC1/porin
and plotted on semi-logarithmic graph. Half-lives were 8.7, 3.4, or 51.7 h following exposure of cells to DMSO, heme, or 4,6-dioxoheptanoic acid (DHA),
respectively. D, the effect of heme (1 M) on ALAS-1 was examined in mitochondria from human liver biopsies. Results of bar graphs are mean  SE.
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detected residual proteasomal activity in our mitochondrial
preparation (supplemental Fig. S2). Therefore, we used a more
specific proteasome inhibitor, epoxomicin, which showed no
effect on LONP1 activity (22). Epoxomicin, at the concentra-
tion that significantly decreased the proteasomal activity in our
mitochondrial preparation (supplemental Fig. S2), did not
affect heme-mediated disappearance of ALAS-1 (Fig. 4D). To
further establish the role of LONP1 protease in the heme-in-
duced decrease in mitochondrial ALAS-1, we silenced the
endogenous LONP1 protease gene by transfecting hepatocytes
with LONP1-specific siRNA pools. As expected, the siRNAs
markedly decreased levels of endogenous LONP1 protein (sup-
plemental Fig. S3A) without significant reduction in the steady
state protein level of ALAS-1 (Fig. 4E). LONP1 knockdown
diminished heme-dependent down-regulation of ALAS-1 pro-
tein (Fig. 4E). siRNA transfection did not alter the 20 S protea-
somal activity (supplemental Fig. S3B), supporting the notion
that proteasome was not responsible for the observed
decrease of ALAS-1 by heme. In other experiments, we
found that exogenous heme (1 M for 8 h) did not affect
levels of LONP1 protein in mitochondrially enriched frac-
tions (supplemental Fig. S4).
DISCUSSION
Previous studies performed by our group showed that in cell
lines of human hepatocellular carcinomas exogenous heme
down-regulates the lower molecular weight band of human
ALAS-1 protein (19), which corresponds to the size of the
mature formALAS-1 located in themitochondria, suggesting a
heme-induced mechanism that controls the fate of the func-
tional form of ALAS-1. In the present study, we further inves-
tigated this possibility in isolated mitochondria where pre-
ALAS-1 is processed into the mature protein and poised for
initiating heme synthesis. Our data indicate that in both human
cell lines and liver tissue heme significantly decreases the half-
life of mitochondrial ALAS-1, whereas in heme-depleted con-
ditions, generated with 4,6-dioxoheptanoic acid pretreatment,
an inhibitor of the second enzyme of the heme biosynthesis
pathway, mitochondrial ALAS-1 exhibited prolonged stability.
Iron and protoporphyrin did not emulate the effect of heme,
and addition of an antioxidant failed to diminish the decrease of
ALAS-1.
Heme has been known to down-regulate ALAS-1 by a nega-
tive feedback loop that involves repression of transcription,
acceleration of mRNA degradation, and impairment of mito-
chondrial import of the protein (1, 2, 7). In the current study, we
demonstrated an additional dimension of posttranslational
regulation of ALAS-1, adding to the complexity of the heme
control of ALAS-1 function. One apparent advantage of such
regulation is the control of ALAS-1 activity inside mitochon-
dria, allowing for very rapid response of the heme biosynthetic
pathway to intramitochondrial levels of heme. Similar findings
in rat liver mitochondria were reported recently (20), suggest-
ing that direct mitochondrial control of ALAS-1 by heme is a
conserved regulatory mechanism across species.
Treating isolated mitochondria with a protease inhibitor
reversed the negative effect of heme on ALAS-1 protein, sug-
gesting that a proteolytic process is involved. We excluded the
possible involvement of proteasomal activity in this process by
using the proteasome-specific inhibitor epoxomicin. Epoxomi-
cin exerted no effect on heme-mediated degradation of
ALAS-1. The turnover of mitochondrial proteins is usually
determined by two pathways: 1) lysosomal degradation via
autophagy and 2)mitochondria-specific protein quality control
system (23, 24). Our results with a cathepsin B inhibitor indi-
cated that the lysosomal system made minimum contribution
to heme-induced ALAS-1 turnover, suggesting that a mito-
FIGURE 3. Effect of iron, free protoporphyrin, oxidative stress, and non-heme synthetic metalloporphyrins on ALAS-1 expression. A, mitochondria from
Huh-7 cells were incubated with FeCl3 (1 M), free protoporphyrin IX (1 M), or heme (1 M) or DMSO for 8 h, and Western immunoblotting analysis was
performed for ALAS-1 expression. Results of bar graph are mean  SE. B, mitochondrial preparations were treated with tert-butyl hydroperoxide solution
(tBuOOH; 1 M), an oxidant for 0, 1, 2, 4, or 8 h, and ALAS-1 expression was determined by Western immunoblotting analysis. C and D, similar experiments were
performed with BHT (10 M), an antioxidant, in the presence or absence of heme (1 M). E, incubation with other metalloporphyrins (1 M), including CoPP,
CrPP, or MnPP, was also performed, and ALAS-1 protein expression was determined by Western immunoblotting analysis. Upper panel, mitochondria from
Huh-7 cells; bottom panel, mitochondria from human liver biopsies.
Heme-mediated Breakdown of Human Mitochondrial ALAS-1
26428 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 30 • JULY 29, 2011
chondrial protease carried out the degradation. It is well estab-
lished that mitochondrially located proteins face constant oxi-
dative challenges due to the presence of inevitable reactive
oxygen species by-products of aerobic respiration; such stress-
induced protein damage and aggregation pose risks to normal
biological functions. Therefore, monitoring for and scavenging
damaged proteins are needed on a continuous basis. However,
compared with the cytosolic protein quality control system,
mitochondrial proteases and chaperones are less well charac-
terized. Our data suggest that LONP1, a nuclearly encoded and
FIGURE 4. Effect of protease inhibitors and siRNAs on ALAS-1 protein expression. A, mitochondrial extracts from Huh-7 cells (75 g of total protein) were
incubated (30 °C) with DMSO or heme (1 M) with or without a protease inhibitor mixture for 8 h. ALAS-1 protein expression was determined by Western
immunoblotting analysis. B, similar studies were performed using the selective cathepsin B inhibitor, CA-074 Me. Mitochondrial extracts (75 g of total protein)
were pretreated for 4 h with 1 M of CA-074 Me, then incubated (30 °C) with DMSO, heme (1 M) with or without a protease inhibitor mixture for 8 h. ALAS-1
protein expression was determined by Western immunoblotting analysis. C, MG-262 inhibits heme-mediated down-regulation of ALAS-1. Mitochondrial
extracts (75 g total protein) were preincubated with or without MG-262 (10 M) for 4 h, then subsequently incubated (30 °C) with heme or DMSO for 8 h.
ALAS-1 protein expression was determined by Western immunoblotting analysis as described under “Experimental Procedures.” D, the effect of epoxomicin on
heme-induced mitochondrial ALAS-1 degradation in mitochondrial extracts. Mitochondrial extracts (75 g total protein) were preincubated with or without
epoxomicin (1 M) for 4 h and then subsequently incubated (30 °C) with heme or DMSO for 8 h. ALAS-1 protein expression was assayed by Western immuno-
blotting analysis. E, LONP1 protease was silenced by transfecting Huh-7 cells with siRNA specific for the LONP1 gene (25 nM). Mitochondrial fractions were
prepared after transfection and incubated (30 °C) with DMSO or heme (1 M in DMSO) for 8 h. ALAS-1/LONP1 protein expression was determined by Western
blot analysis. Results of bar graphs are mean  SE.
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mitochondrially located stress-responsive protease, is involved
in heme-mediated ALAS-1 turnover. Mammalian Lon1 prote-
ase is a homologue of bacterial protease La and yeast PIM1 and
has been implicated throughout evolution in the degradation of
stress-damaged mitochondrial enzymes (25). A second ATP-
dependent matrix protease identified to date is ClpXP. Thus
far, no physiologically significant substrates have been assigned
to mammalian ClpXP. We do not exclude the possibility that
other mitochondrial protease systems are also involved in
heme-ALAS-1 regulation.
Themolecularmechanism of heme-mediatedmitochondrial
ALAS-1 degradation also calls for further investigation. How
ALAS-1 in presence of heme overload is marked for degrada-
tion remains unanswered. The lack of effect of iron or free por-
phyrin and the observation that the down-regulating activity of
heme is separate from redox regulation point to a mechanism
by which the entire heme macrocycle is required as a signaling
molecule. Heme as a prosthetic group affects the function and
fate ofmany proteins.Noteworthy examples include the impor-
tant mammalian transcription repressor Bach1 and yeast tran-
scription activator HAP1 (26, 27). ALAS-1 has three CP motifs
known as heme regulatory motifs, one in the N terminus of the
mature protein and two in the leader sequence of the preprotein.
The functional role of theseCPmotifs inALAS-1hasbeen studied
in respect to heme regulation of mitochondrial translocation (17,
18). Similar CP motifs have been identified in Bach1 and HAP1
and shown to regulate the activity of these proteins. We plan to
examine whether the CP motif functions as a heme sensor and
mediates the heme effect onmitochondrial ALAS-1.
Another aspect that needs to be taken into consideration
involves mitochondrial matrix protein processing. Like most
mitochondrial matrix proteins, ALAS-1 is synthesized on the
rough endoplasmic reticulum and subsequently transferred
across the outer and innermembranes ofmitochondria, a proc-
ess requiring additional processing by peptidases and protec-
tion by chaperones for proper folding.Whether heme regulates
presequence processing and how that would affect ALAS-1 sta-
bility and function are also in need of further examination. Our
present experimental systemwas not designed to address these
issues and future research is warranted.
Heme infusion is the standard therapy for acute porphyrias
but its effect is often short-lived due to the activation of heme
oxygenase-1 and sometimes associated with undesirable side
effects. Indeed, recent studies in our laboratory show that heme
treatment increasesmRNA expression of several proinflamma-
tory genes and stress response genes.4 Many synthetic metallo-
porphyrins are structurally related to heme but display varied
activity toward activating heme oxygenase and inducing
adverse reactions. Non-hememetalloporphyrins, therefore, are
considered potential alternatives for the effective treatment of
porphyria. We also examined the effect of other metallopor-
phyrins on ALAS-1 protein expression; we found that three
transition metal-complexed porphyrins, namely CoPP, CrPP,
and MnPP, also down-regulate mitochondrial ALAS-1 to vari-
ous extents. CoPP and CrPP have been shown to regulate
ALAS-1mRNA levels (19). A better understanding of hownon-
heme metalloporphyrins work is essential for developing new
therapeutic strategies.
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